<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; ban</title>
	<atom:link href="http://www.tapanray.in/tag/ban/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Closed Doors, Open Channels: India’s Ban on Medical Reps in Govt Hospitals Reshapes Pharma Engagement</title>
		<link>http://www.tapanray.in/closed-doors-open-channels-indias-ban-on-medical-reps-in-govt-hospitals-reshapes-pharma-engagement/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=closed-doors-open-channels-indias-ban-on-medical-reps-in-govt-hospitals-reshapes-pharma-engagement</link>
		<comments>http://www.tapanray.in/closed-doors-open-channels-indias-ban-on-medical-reps-in-govt-hospitals-reshapes-pharma-engagement/#comments</comments>
		<pubDate>Fri, 06 Jun 2025 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[email]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[Govt]]></category>
		<category><![CDATA[hospitals]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[India’s Ban MR]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reps]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10909</guid>
		<description><![CDATA[The June 3, 2025, directive from the Directorate General of Health Services (DGHS), banning medical representatives (MRs) from meeting doctors in central government hospitals, marks a pivotal policy shift in India&#8217;s evolving healthcare ecosystem. It signals a firm step toward &#8230; <a href="http://www.tapanray.in/closed-doors-open-channels-indias-ban-on-medical-reps-in-govt-hospitals-reshapes-pharma-engagement/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/closed-doors-open-channels-indias-ban-on-medical-reps-in-govt-hospitals-reshapes-pharma-engagement/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>For Improving Drug Quality in India &#8211; A Bizarre Intent</title>
		<link>http://www.tapanray.in/for-improving-drug-quality-in-india-a-bizarre-intent/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=for-improving-drug-quality-in-india-a-bizarre-intent</link>
		<comments>http://www.tapanray.in/for-improving-drug-quality-in-india-a-bizarre-intent/#comments</comments>
		<pubDate>Sun, 28 Jan 2018 23:43:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[bizarre]]></category>
		<category><![CDATA[bulk]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Chinese]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Delhi]]></category>
		<category><![CDATA[DI]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[facilities]]></category>
		<category><![CDATA[Fake]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inspection]]></category>
		<category><![CDATA[Inspectors]]></category>
		<category><![CDATA[Kerala]]></category>
		<category><![CDATA[Maharashtra]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Misplaced]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[plants]]></category>
		<category><![CDATA[Priority]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Shortages]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[substandard]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8778</guid>
		<description><![CDATA[On January 16, 2017, quoting a Government source, a media report revealed, “India&#8217;s drug regulator is looking to inspect US pharmaceutical facilities, making critical medicines so that only high-quality products are imported from them.” This intent follows a similar decision &#8230; <a href="http://www.tapanray.in/for-improving-drug-quality-in-india-a-bizarre-intent/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/for-improving-drug-quality-in-india-a-bizarre-intent/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is The Global Generic Drug Market Slowing Down?</title>
		<link>http://www.tapanray.in/is-the-global-generic-drug-market-slowing-down/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-the-global-generic-drug-market-slowing-down</link>
		<comments>http://www.tapanray.in/is-the-global-generic-drug-market-slowing-down/#comments</comments>
		<pubDate>Sun, 04 Jun 2017 23:55:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[containment]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[down]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[elf]]></category>
		<category><![CDATA[expiration]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[hikes]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inflicted]]></category>
		<category><![CDATA[injury]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[murmurs]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[slowing]]></category>
		<category><![CDATA[Standard]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trend]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8258</guid>
		<description><![CDATA[Driven by a strong environmental headwind, both within and outside the country, several pharma companies in India have recently started raising a red flag on their future earning guidance for the stock market, though citing quite different reasons altogether. Quoting &#8230; <a href="http://www.tapanray.in/is-the-global-generic-drug-market-slowing-down/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-the-global-generic-drug-market-slowing-down/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Escalating Antibiotic Resistance, And Thwarting Ban Of Irrational FDCs</title>
		<link>http://www.tapanray.in/escalating-antibiotic-resistance-and-thwarting-bans-of-irrational-fdcs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=escalating-antibiotic-resistance-and-thwarting-bans-of-irrational-fdcs</link>
		<comments>http://www.tapanray.in/escalating-antibiotic-resistance-and-thwarting-bans-of-irrational-fdcs/#comments</comments>
		<pubDate>Sun, 20 Nov 2016 23:35:17 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[antibiotic]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Combination]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Dose]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[escalating]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[Fixed]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[irrational]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[National Policy for Containment of Antimicrobial Resistance in India]]></category>
		<category><![CDATA[New Delhi metallo-β-lactamase]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[resistance]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[thwarting]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7973</guid>
		<description><![CDATA[September 2016 ‘Fact Sheet’ of the World Health Organization (W.H.O) raised a red flag on fast increasing incidence of Antimicrobial Resistance (AMR). It poses a serious threat to global public health, more than ever before. Consequently, effective prevention and treatment &#8230; <a href="http://www.tapanray.in/escalating-antibiotic-resistance-and-thwarting-bans-of-irrational-fdcs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/escalating-antibiotic-resistance-and-thwarting-bans-of-irrational-fdcs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>&#8216;Indian Drug Control World’s Weakest: Pharma Trade Bodies Working At Cross Purposes&#8217;</title>
		<link>http://www.tapanray.in/indian-drug-control-worlds-weakest-pharma-trade-bodies-working-at-cross-purposes/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indian-drug-control-worlds-weakest-pharma-trade-bodies-working-at-cross-purposes</link>
		<comments>http://www.tapanray.in/indian-drug-control-worlds-weakest-pharma-trade-bodies-working-at-cross-purposes/#comments</comments>
		<pubDate>Mon, 25 Apr 2016 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[associations]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[bodies]]></category>
		<category><![CDATA[center]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Corruption]]></category>
		<category><![CDATA[cross-purposes]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Editorial]]></category>
		<category><![CDATA[Edmund]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[mandatory]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Ministers]]></category>
		<category><![CDATA[Office]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PMO]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[PTI]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[Safra]]></category>
		<category><![CDATA[secretary]]></category>
		<category><![CDATA[Subburaj]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[Voluntary]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7612</guid>
		<description><![CDATA[&#8220;In the entire world, I think our drug control system probably is the weakest today. It needs to be strengthened,&#8221; said the Secretary of the Department of Pharmaceuticals (DoP) &#8211; V K Subburaj at an event in New-Delhi on April &#8230; <a href="http://www.tapanray.in/indian-drug-control-worlds-weakest-pharma-trade-bodies-working-at-cross-purposes/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indian-drug-control-worlds-weakest-pharma-trade-bodies-working-at-cross-purposes/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Ease of Doing Pharma Business in India: A Kaleidoscopic View </title>
		<link>http://www.tapanray.in/ease-of-doing-pharma-business-in-india-a-kaleidoscopic-view/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=ease-of-doing-pharma-business-in-india-a-kaleidoscopic-view</link>
		<comments>http://www.tapanray.in/ease-of-doing-pharma-business-in-india-a-kaleidoscopic-view/#comments</comments>
		<pubDate>Mon, 28 Mar 2016 00:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Delhi]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[doing]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[ease]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[evergreening]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[irration]]></category>
		<category><![CDATA[Kaleidoscope]]></category>
		<category><![CDATA[Kaleidoscopic]]></category>
		<category><![CDATA[mandatory]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7552</guid>
		<description><![CDATA[Ensuring ease of doing any ethical business activity in India, is a new focus area of the Government and is very rightly so. Creating ease of doing ethical pharma business too, falls under this overall national objective. In this article, &#8230; <a href="http://www.tapanray.in/ease-of-doing-pharma-business-in-india-a-kaleidoscopic-view/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/ease-of-doing-pharma-business-in-india-a-kaleidoscopic-view/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Recent Ban On Irrational FDCs: History Repeats Itself</title>
		<link>http://www.tapanray.in/the-recent-ban-on-irrational-fdcs-history-repeats-itself/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-recent-ban-on-irrational-fdcs-history-repeats-itself</link>
		<comments>http://www.tapanray.in/the-recent-ban-on-irrational-fdcs-history-repeats-itself/#comments</comments>
		<pubDate>Mon, 21 Mar 2016 00:00:49 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[294]]></category>
		<category><![CDATA[344]]></category>
		<category><![CDATA[59th]]></category>
		<category><![CDATA[ADE]]></category>
		<category><![CDATA[ADR]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[AWACS]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Combination]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Corex]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Delhi]]></category>
		<category><![CDATA[Dose]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[DTAB]]></category>
		<category><![CDATA[evidence]]></category>
		<category><![CDATA[FDCs]]></category>
		<category><![CDATA[Fixed]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[history]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[injunction]]></category>
		<category><![CDATA[interim]]></category>
		<category><![CDATA[irrational]]></category>
		<category><![CDATA[itself]]></category>
		<category><![CDATA[Kokate]]></category>
		<category><![CDATA[madras]]></category>
		<category><![CDATA[Ministry]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[repeats]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Sri Lanka]]></category>
		<category><![CDATA[stay]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7543</guid>
		<description><![CDATA[The recent regulatory ban on a large number of irrational Fixed Dose Combination (FDC) drugs is not a new incident in India. A similar mega ban was announced even before, about nine years ago. Intriguingly, the saga continues, for various &#8230; <a href="http://www.tapanray.in/the-recent-ban-on-irrational-fdcs-history-repeats-itself/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-recent-ban-on-irrational-fdcs-history-repeats-itself/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Data Manipulation: Leapfrogging Dangerously Into Clinical Trial Domain</title>
		<link>http://www.tapanray.in/data-manipulation-leapfrogging-dangerously-into-clinical-trial-domain/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=data-manipulation-leapfrogging-dangerously-into-clinical-trial-domain</link>
		<comments>http://www.tapanray.in/data-manipulation-leapfrogging-dangerously-into-clinical-trial-domain/#comments</comments>
		<pubDate>Mon, 03 Aug 2015 00:00:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[700]]></category>
		<category><![CDATA[Aurobindo]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[cadila]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[emcure]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[GCP]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[GMP]]></category>
		<category><![CDATA[GVK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Jugaad]]></category>
		<category><![CDATA[Leapfrog]]></category>
		<category><![CDATA[Leapfrogging]]></category>
		<category><![CDATA[lifesciences]]></category>
		<category><![CDATA[Make in India]]></category>
		<category><![CDATA[Malpractice]]></category>
		<category><![CDATA[manipulation]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[MHRA]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[pharmexcil]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[quest]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[rigmarole]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6908</guid>
		<description><![CDATA[Over the last several years, repeated allegations of gross data manipulative practices, detected by global drug regulatory agencies, such as USFDA and MHRA, have shaken the Indian pharma exporting companies hard. This has been hurting the overall business performance of &#8230; <a href="http://www.tapanray.in/data-manipulation-leapfrogging-dangerously-into-clinical-trial-domain/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/data-manipulation-leapfrogging-dangerously-into-clinical-trial-domain/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Booming Sales Of Unapproved Drugs: Do We Need “Safe In India” Campaign For Medicines?</title>
		<link>http://www.tapanray.in/booming-sales-of-unapproved-drugs-do-we-need-safe-in-india-campaign-for-medicines/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=booming-sales-of-unapproved-drugs-do-we-need-safe-in-india-campaign-for-medicines</link>
		<comments>http://www.tapanray.in/booming-sales-of-unapproved-drugs-do-we-need-safe-in-india-campaign-for-medicines/#comments</comments>
		<pubDate>Mon, 18 May 2015 00:00:54 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[Abraham]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[booming]]></category>
		<category><![CDATA[campaign]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Combination]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Dose]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[Fixed]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[journal]]></category>
		<category><![CDATA[Lincoln]]></category>
		<category><![CDATA[may]]></category>
		<category><![CDATA[medicines. PLOS]]></category>
		<category><![CDATA[mission]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Peer]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reviewed]]></category>
		<category><![CDATA[Safe in India]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[Statement]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[unapproved]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6622</guid>
		<description><![CDATA[“To sin by silence when they should protest makes cowards of men”                      - Abraham Lincoln Not just the Federal Drug Administration of the United States (USFDA), global concerns are being expressed &#8230; <a href="http://www.tapanray.in/booming-sales-of-unapproved-drugs-do-we-need-safe-in-india-campaign-for-medicines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/booming-sales-of-unapproved-drugs-do-we-need-safe-in-india-campaign-for-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Sets 2013, Dawns 2014: Top 7 Pharma Developments</title>
		<link>http://www.tapanray.in/sets-2013-dawns-2014-top-7-pharma-developments/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=sets-2013-dawns-2014-top-7-pharma-developments</link>
		<comments>http://www.tapanray.in/sets-2013-dawns-2014-top-7-pharma-developments/#comments</comments>
		<pubDate>Mon, 30 Dec 2013 23:20:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[2014]]></category>
		<category><![CDATA[back]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Crystal]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[expiry]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[Gazing]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[heralds]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Looking]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[PPP]]></category>
		<category><![CDATA[prescriptions]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[recounts]]></category>
		<category><![CDATA[revoke]]></category>
		<category><![CDATA[salient]]></category>
		<category><![CDATA[sets]]></category>
		<category><![CDATA[Seven]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4721</guid>
		<description><![CDATA[Wish You Good Health, Happiness, Success and Prosperity in 2014 In this article I shall focus on &#8216;Top 7 Pharma Developments’, both while ‘Looking Back to 2013&#8242; and also during my ‘Crystal Gazing 2014&#8242;. Looking Back to 2013: While looking &#8230; <a href="http://www.tapanray.in/sets-2013-dawns-2014-top-7-pharma-developments/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/sets-2013-dawns-2014-top-7-pharma-developments/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
